Expression and prognostic significance of programed cell death ligand 1 (PD-L1) in ovarian cancer

[B. V. Gutić]

70, [13] str.

medicina - Humana reprodukcija, perinatologija i neonatologija / medicine - Human reproduction, perinatology and neonatology

Uvod. Karcinom jajnika predstavlja relativno redak malignitet sa visokim mortalitetom. Nejasna etiopatogeneza jedan je od razloga što ciljana terapija još uvek nije zauzela značajno mesto u lečenju ovih pacijentkinja. Metod. Istraživanje je kohortna studija u kojoj je analizirana ekspresija PD-L1 i njen prognostički značaj kod obolelih od karcinomom jajnika. Retrospektivni deo istraživanja uključio je prikupljanje demografskih podataka, informacija o kliničko-patološkim karakteristikama tumora, načinu lečenja i ishodu bolesti. Kod selektovanih pacijentkinja prospektivno je analiziran status PD-L1 receptora u tumorskom tkivu. Analizirana je ekspresija PD-L1 u uzorku, kao i njegova povezanost sa kliničkopatološkim karakteristikama tumora, odgovorom na primarni tretman i ishodom bolesti. Rezultati. Ekspresija u ispitivanom uzorku bila je prisutna na 53% tumor infiltrišućih limfocita (TIL), 40% tumor asociranih makrofaga i 21% tumorskih ćelija. Kod karcinoma ovarijuma tip1 u FIGO stadijumu III i IV primetna je nesignifikantno manja ekspresija PD-L1 na tumor infiltrišućim limfocitima i tumor infiltrišućim makrofagima. Ekspresija PDL-1 u tumorskim ćelijama (χ2 (2) = 7,50, p = ,024) bila je statistički značajno povezana sa odgovorom na terapiju. Pokazana je marginalna značajnost (LRT (1) = 1,36, p < ,05) u preživljavanju pacijentkinja u odnosu na PD-L1 ekspresiju na tumorskim ćelijama sa protokom vremena. Zaključak. Ekspresija PD-L1 je najučestalija na tumor infiltrišućim limfocitima. Eskpresija PD-L1 na tumorskim ćelijama je značajno pozitivno povezana sa odgovorom na standardnu terapiju. Sa protokom vremena praćenja veću verovatnoću preživljavanja imaju pacijentkinje bez eksprimiranog PD-L1.

Introduction. Ovarian cancer has relatively low incidence but high mortality. Undefined etiopathogenesis is one of the reasons that target treatment still did not take a significant place in ovarian cancer treatment. Methods. Research is a cohort study which analized PD-L1 expression and it’s prognostic role in ovarian cancer patients. Retrospective part of the research included collecting demographic data of patients, informations of clinical and pathological caracteristics of the tumor, implemented treatment and outcome. PD-L1 receptor status in the tumor tissue was analyzed for the selected patients. Relation of PDL1 expression and clinical and pathological data was analyzed as well as the relation of PD-L1 expression with respond to standard treatment and outcome of disease. Results. There was 53% tumor infiltrating lymphocytes (TIL) with PD-L1 expression, 40% tumor assosiated macrophages and 21% tumor cells. Difference in PD-L1 expresion for ovarian cancer type 1 and 2 in advance stages ovarian cancer was insignificantly lower in type 1 for TIL and tumor assosiated macrophages. There was statistically significant relation of PD-L1 expression on tumor cells and respond to standar treatment (χ2 (2) = 7.50, p = .024). Survival analysis showed marginally significance (LRT (1) = 1,36, p < ,05) benefit for patients without PD-L1 expression after two years follow up. Conclusions. PD-L1 expression was most common on TIL. There was significant relation of PD-L1 expression on tumor cells and respond to standard treatment. After two years follow up there was higher survival probability for patients without PD-L1 expression.

karcinom jajnika, etiopatogeneza karcinoma, PD-L1 ekspresija, imunologija karcinoma jajnika

ovarian cancer, cancer etiopathogenesis, PD-L1 expression, ovarian cancer immunology

618.11-006.6:577.2(043.3)

Tekst